Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel.
IFNα and nadofaragene firadenovec can provide a new therapy approach for a disease with a significant unmet clinical need.
BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC.
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
Kyle M. Rose, MD, describes how cell-free DNA is used to detect MRD prior to repeat-transurethral resection in NMIBC.
A recent study analyzed the effectiveness of BCG treatment in patients with NMIBC, including a subgroup of patients with CIS.
Joshua Meeks, MD, PhD, discusses ongoing research in NMIBC and the future of urothelial carcinoma care.
Researchers developed a randomized phase II clinical trial for patients with NMIBC before transurethral resection of tumors.
Colin Dinney, MD, explains the data that led to FDA approval of Adstiladrin for NMIBC and how it impacts the treatment.
By administering immediate single-dose intravesical chemotherapy, there is a 15% absolute risk reduction in tumor recurrence.
The FDA approved Adstiladrin, a gene therapy for the treatment of adult patients with high-risk BCG-unresponsive NMIBC.
Endoscopic balloon cryoablation is an effective therapy for transurethral resection of non-muscle invasive bladder cancer.
The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes.
A study analyzing the safety and efficacy of large surface area microparticle docetaxel for NMIBC is reviewed.
Researchers evaluated the safety and efficacy of intravesical pembrolizumab when in conjunction with intravesical BCG.
Short-term intensive chemoresection, a nonsurgical treatment modality, treated recurrent NMIBC, reducing required procedures.
The induction lymphocyte-to-monocyte ratio was associated with “better accuracy” and than the preoperative ratio.
While BCG has been the standard adjuvant therapy for patients with high-risk NMIBC, a shortage has led to other regimens.
The current standard of care for patients with high-grade NMIBC, intravesical Bacillus Calmette-Guérin, is discussed.
Pathogenic variants were more common in patients who had high-grade NMIBC than in patients with low-grade NMIBC.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726